Share price information Amryt Pharma is traded on Nasdaq and the London Stock Exchange’s AIM Market ADS Conversion Frequently Asked Questions Download ADS Conversion Frequently Asked Questions document >> Major shareholders Major shareholders are as follows (interest as at 4 January 2021). Name Number of shares % of issued share capital Funds managed by Athyrium Capital Management, LP 44,286,346 24.8% Funds managed by Highbridge Capital Management LLC 15,732,313 8.8% Novelion Therapeutics Inc 12,490,250 7.0% Edgepoint Investment Group Inc. 12,126,650 6.8% Stonepine Capital Management, LLC 11,082,415 6.2% Software AG-Stiftung 10,212,153 5.7% Funds managed by UBS O’Connor LLC 9,950,000 5.6% Amati 6,860,513 3.8% AXA Investment Management 6,494,164 3.6% On October 31, 2021 the issued share capital of the Company comprised 317,999,117 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company at October 31, 2021 was 317,999,117. This figure of 317,999,117 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules. Pursuant to the AIM rules, and insofar as the Company is aware, as at 30 June 2021, 28.39% of the Company’s issued share capital is not in public hands. Restrictions: there are no restrictions on the transfer of Ordinary Shares. Takeover Code: the Company is subject to the City Code on Takeovers and Mergers. Form 8937 (2021) We transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need. Privacy policy | Terms and Conditions Cookie policy | Fraud warning Accessibility | Sitemap Website Last updated: 04/08/2021 | Copyright © 2021 Amryt Pharma plc We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All

Register for email alerts We transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need. Privacy policy | Terms and Conditions Cookie policy | Fraud warning Accessibility | Sitemap Website Last updated: 04/08/2021 | Copyright © 2021 Amryt Pharma plc We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. Cookie Settings Accept All